3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
34
Leukemia
15
Gastrointestinal Stromal Tumors
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myeloid, Chronic-Phase
7
Philadelphia Chromosome
4
Leukemia, Myeloid
4
Bone Marrow Diseases
4
Neoplasms
3
Myeloproliferative Disorders
3
Hematologic Diseases
3
Melanoma
2
Hematologic Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Blast Crisis
2
Synovitis, Pigmented Villonodular
1
Recurrence
1
Piebaldism
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplastic Processes
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Mastocytosis, Systemic
1
Leukemia, Myeloid, Accelerated Phase
1
Hypereosinophilic Syndrome
1
Glioma
1
Interventions
nilotinib
1
Zoledronic Acid
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplastic Processes
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA